LatAm-EAS webinar series

Welcome to the LatAm-EAS webinar series! This series serves as a dynamic platform bridging insights and discussions between Latin America region and our society’s experts. With a focus on fostering collaboration, understanding, and innovation, our series offers a diverse range of topics explored through four engaging webinars, each presented in both English and Spanish.

Learn more about particular webinars (their programmes, speakers and chairs) by clicking on the corresponding banners:





#1 Global Epidemic of Obesity and Cardiovascular Disease: The heart of the problem

May 8, 2024 at 18:00 CET

Language: English (subtitles in Spanish)

By defining obesity as a chronic disease, the World Health Organization (WHO) has significantly contributed to dissociating it from a simplistic perspective, wherein its carriers are socially stigmatized and victims of prejudices harmful to self-esteem. Obesity is indeed a disease of epidemic proportions in our time – a true public health emergency, characterized by an excess of adiposity capable of seriously impairing health. It is a condition associated with several morbid consequences and should be addressed in light of the best medical evidence. 

This webinar is aimed at addressing the obesity burden from an epidemiological perspective, the pathophysiological derangements that link ectopic adiposity with heart and kidney diseases, and the therapeutic strategies to tackle this challenge.

Register here


18:00 Introduction to the webinar

18:05 Overweight and obesity burden: A global and Latin American perspective, José Francisco Kerr Saraiva

18:20 The link between obesity and cardio-renal injury: New insights into pathophysiology, Marianne Benn

18:35 Reduction of cardiovascular risk in people living with obesity: What works and what doesn’t, Naveed Sattar

18:50 Discussion and Q&A


Sergio Kaiser

Associate Professor of Internal Medicine at the Rio de Janeiro State University, where he coordinates the discipline of Clinical and Experimental Pathophysiology. His main interests are preventive cardiology, with a special focus on dyslipidemia and atherosclerosis, as well as heart failure.

He has taken part in the elaboration of positioning documents led by the Brazilian Society of Cardiology, as well as in national guidelines, such as the Brazilian Guidelines of Hypertension and Brazilian Guidelines of Preventive Cardiology.

He is a fellow of the American College of Cardiology, fellow of the European Society of Cardiology, and member of the European Atherosclerosis Society (EAS) to which he has contributed as a Social Media Ambassador. He has also been recently invited to be the national coordinator in Brazil, of the EAS Lipid Clinic Network.

Fabiana Rached

Cardiologist at the Atherosclerosis Clinical Unit of the Heart Institute (InCor) at the University of São Paulo.

PhD in Science from the University of São Paulo and from Université Pierre et Marie Curie (Paris, France).


José Francisco Kerr Saraiva

Cardiologist, Professor of Clinical Cardiology at the Pontifical Catholic School of Medicine of Campinas.

National Leader of FOURIER Trial, and the primary investigator of IMPROVE-IT. ODYSSEY Diabetes and ODYSSEY Kids Trial Principal Investigator and SC member of CVOT’S evolving DPP-4 Inhibitors, SGLT-2 Inhibitors, GLP-1 Analogues, and Glitazones.

President of the Atherosclerosis Department of the Brazilian Society of Cardiology.

Marianne Benn

MD Ph.D., DMSc, Senior Consultant at Department of Clinical Biochemistry, Rigshospitalet, Copenhagen; Professor in Clinical Biochemistry with a special focus on Translational Medicine; and co-chair of the BRIDGE – Translational Excellence Programme at University of Copenhagen, Denmark.

Naveed Sattar

Professor of Metabolic Medicine at the School of Cardiovascular & Metabolic Health.

Endocrinologist, and Honorary Consultant in Metabolic Medicine at the Glasgow Royal Infirmary, where he co-leads a CVD prevention clinic.

He is a Fellow of the Royal College of Pathologists; the Royal College of Physicians and Surgeons, Glasgow; the Royal Society of Edinburgh; and the UK Academy of Medical Sciences.

#2 Challenges in achieving control of lipid disorders in LatAm

June 26, 2024 at 18:00 CET

Language: English and Spanish

Atherosclerotic cardiovascular diseases (ASCVD), including myocardial infarction, stroke, and peripheral arterial disease, remain major causes of death in LATAM. The primary strategy for preventing ASCVD involves averting the accumulation of cholesterol-containing atherogenic lipoproteins in the vessel wall. Extensive, well-designed, placebo-controlled studies have demonstrated that lowering LDL cholesterol levels reduces cardiovascular events. 

Given the significant number of patients requiring lipid-lowering therapy, a crucial question arises: Are we effectively treating LDL cholesterol levels to attain the desired goals?

In this webinar, we will delve into dyslipidemia as a cardiovascular risk in LATAM. We will discuss LDL cholesterol goals recommended by recent guidelines, focusing on the barriers hindering the achievement of these goals. Moreover, we will emphasize the necessity of identifying the main barriers to getting patients to their goals and controlling cardiovascular risk factors to prevent major cardiovascular events. Additionally, the webinar will explore potential solutions to overcome these challenges.

Register here


18:00 Introduction of the webinar  

18:05 Dyslipidemia and cardiovascular risk (epidemiology of dyslipidemia in LATAM and associated cardiovascular risk), Isabel Cristina Càrdenas

18:20 What are the therapeutic objectives of LDL, Non-HDL cholesterol, lipoprotein (a), and apolipoprotein B according to cardiovascular risk?, Dora Inés Molina de Salazar

18:35 Barriers to Achieving LDL Cholesterol Goals in LATAM, Isabel Cristina Càrdenas & Dora Inés Molina de Salazar

18:50 Discussion and Q&A


Ángel Alberto García Peña

MD, Msc, PhD (c), FACC, Internal Medicine, Cardiology, Epidemiology, Heart Failure, and Cardiac Transplantation. San Ignacio University Hospital. Pontifical Javeriana University. Bogotá. Colombia

Luz Clemencia Zárate C.

MD, Internal Medicine, Cardiology, Master Degree in Lipids and Cardiooncology. Univalle University. Cali, Colombia

Alberto Zambon

Endocrinologist. Associate Professor of Medicine, Department of Medicine – University of Padua School of Medicine – Italy.

PhD in Gerontology from the University of Padua (1998). Post-Doctoral Fellow at the Division of Endocrinology, Metabolism and Nutrition, School of Medicine, University of Washington, Seattle.


Isabel Cristina Càrdenas

MD, Internal Medicine, Cardiology, Master degree in Heart Failure. Colombıa Clinic. Bogotà, Colombia

Dora Inés Molina de Salazar

MD, MPH, PhD, FACP, Internal Medicine, Professor Caldas University. Fellow Latin-American Society of Hypertension (LASH). Chapter Governor American College of Physicians.

PI Clinical Research, IPS Médicos Internistas de Caldas SAS.

#3 Triglyceride-rich lipoproteins as contributors to residual risk

September 5, 2024 at 18:00 CET

Language: English and Spanish

There have long been debates regarding the atherogenic role of triglyceride-rich lipoproteins (TRL) and whether mild or moderate increases should be addressed pharmacologically. While not all the mechanisms explaining the residual risk are known, TRLs are believed to play a significant role. Gaining a better understanding of the effects of TRL on the atherosclerotic process is crucial for enhancing our knowledge of how to manage hypertriglyceridemia.

Register here


18:00 Introduction to the webinar

18:05 Potential atherogenicity of triglyceride-rich lipoproteins, Laura Schreier

18:25 TG-rich lipoproteins: star or second advantage in the field of residual CV risk?, Alberto Zambon

18:45 Discussion and Q&A


Pablo Corral

Internal Medicine and Lipid specialist physician; he coordinates the Lipids and Atherosclerosis Department at the ICM Institute, Mar del Plata, Argentina. He is Professor at FASTA University, School of Medicine, Pharmacology & Research Department. He is the past president of the Argentina Lipid Society.

His research interests focus on Lipids, Atherosclerosis and Cardiovascular Disease prevention, including Familial Hypercholesterolemia, Residual Risk and genetics dyslipidemias. Notably, he is member of the Red IberoAmericana de Hipercolesterolemia Familiar (IberoAmerica FH Network), Lipid and Cardiology Argentine Societies, as well as a number of expert societies including European Atherosclerosis Society (EAS).

He has published more than 50 papers in lipid field and he is an active participant of different cardiovascular meetings as speaker. 


Laura Schreier

Full Professor at the University of Buenos Aires, Director of the Department of Clinical Biochemistry, Chief of the Laboratory of Lipids and Atherosclerosis – University of Buenos Aires, and belongs to the Institute of Pathophysiology and Clinical Biochemistry, INFIBIOC-UBA.

Laura does research in Lipids, Lipoproteins, Metabolic and Cardiovascular risk.

Alberto Zambon

Endocrinologist. Associate Professor of Medicine, Department of Medicine – University of Padua School of Medicine – Italy.

PhD in Gerontology from the University of Padua (1998). Post-Doctoral Fellow at the Division of Endocrinology, Metabolism and Nutrition, School of Medicine, University of Washington, Seattle.

#4 How to improve the quality of care for patients with dyslipidemia?

December 11, 2024 at 20:00 CET

Language: English and Spanish

Long-term adherence to lipid-lowering therapy poses one of the greatest challenges in cardiovascular prevention. The effectiveness of therapy heavily depends on the individualization of medical treatment, the identification and resolution of barriers that prevent full treatment adoption, and the implementation of best practices in medical services. Cultural issues and peculiarities of care delivery systems hinder the universal application of the same strategies.

This symposium will feature a review of the variability in the effectiveness of lipid-lowering therapy around the world. Additionally, examples of best practices implemented in Europe and Latin America will be described. All presentations will be given by highly recognized leaders in the field, representing the European Atherosclerosis Society and the EAS LATAM group.

Register here


20:00 Introduction to the webinar

20:05 Effectiveness of lipid-lowering therapies around the world. Kausik K. Ray

20:30 Actions to improve the quality of care for patients with dyslipidemia: The Case for Europe. Alexandros Tselepis

20:50 Actions to improve the quality of care for patients with dyslipidemia: The Case for Latin America. Andrei Sposito

21:10 Discussion and Q&A 


Carlos A. Aguilar Salinas

Founder of the Lipid Clinic and the current Head of Nutrition at the Instituto Nacional de Ciencias Medicas y Nutricion (INCMNSZ), Mexico City


Kausik K. Ray

Professor, BSc(hons), MBChB, MD, MPhil (Cantab), FRCP (Lon), FRCP (Ed), FACC, FESC, FAHA

Professor of Public Health at the School of Public Health, the Director of the Imperial Centre for Cardiovascular Disease Prevention and the Deputy Director of the Imperial Clinical Trial Unit, Imperial College London and a Consultant Cardiologist.

Alexandros Tselepis

Professor of Biochemistry-Clinical Chemistry University of Ioannina, Greece
Director of the Atherothrombosis Research Centre of the University of Ioannina, Greece

Andrei Sposito

MD, PhD, Director of Atherosclerosis and Vascular Biology Lab na FCM – UNICAMP, Universidade Estadual de Campinas